|
|
|
Hybrid ribozymes as therapeutics
Scientists have long toyed with the idea of putting to work a special class of biological catalysts, called ribozymes, as therapeutic agents. These molecular scissors would harness the activities of overly active genes that contribute to diseases like cancer by cutting their immediate products, messenger RNAs, into unusable pieces. The advantage of this approach, is that these molecules can be made to recognize very specific targets. This is reported in this month issue of EMBO reports. Contact:
Ellen Peerenboom
ellen.peerenboom@embo.org
49-622-188-91108
European Molecular Biology Laboratory
Message posted by: Wouter Kalle
|
|
Variants Associated with Pediatric Allergic Disorder
Mutations in PHF6 Found in T-Cell Leukemia
Genetic Risk Variant for Urinary Bladder Cancer
Antibody Has Therapeutic Effect on Mice with ALS
Regulating P53 Activity in Cancer Cells
Anti-RNA Therapy Counters Breast Cancer Spread
Mitochondrial DNA Diversity
The Power of RNA Sequencing
‘Pro-Ageing' Therapy for Cancer?
Niche Genetics Influence Leukaemia
Molecular Biology: Clinical Promise for RNA Interference
Chemoprevention Cocktail for Colon Cancer
more news ...
|